Meeting
2022 ASCO Annual Meeting
A multicenter, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.
Authors
Xiaojie Hu
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Xiaojie Hu , Kang Zeng , Zhongyuan Xu , Wenbin Li , Changxing Li , Zhuang Kang , Shenglan Li , Ai-Min Hui , Zhuli Wu , Xin Huang , Pu Han , Ben Li , Xiaoxi Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04954001
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3011)
DOI
10.1200/JCO.2022.40.16_suppl.3011
Abstract #
3011
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A multicenter, open-label, single-arm, phase 1 dose-escalation and phase 2 dose-expansion study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.
First Author: Xiaojie Hu
Poster
2023 ASCO Annual Meeting
![FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose <i>e</i>scalation study for treatment of patients with select solid tumors.](https://d201v5jt9ylckg.cloudfront.net/299/15000/225830/225830_A945_poster_pv.jpg)
FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.
First Author: Lisa Bodei
Poster
2023 ASCO Annual Meeting
A phase I trial of diphencyprone for cutaneous neurofibromas in adult patients with neurofibromatosis type 1.
First Author: Dina Poplausky
Poster
2024 ASCO Annual Meeting
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.
First Author: Andrae L. Vandross